Zimmer Biomet Holdings, Inc (ZBH) Q1 2026 Earnings Call Transcript

Why It Matters

The earnings beat and raised guidance underscore Zimmer Biomet’s ability to drive profitable growth through product innovation and commercial transformation, signaling continued momentum for investors and the orthopedic market.

Key Takeaways

• Net sales reached $2.087 billion, up 9.3% YoY.
• Adjusted EPS rose 15% to $2.09, tariff benefit included.
• U.S. partial knee sales jumped over 20% on Oxford product.
• Paragon 28 acquisition accelerated, adding 200 bps growth Q1.
• Adjusted EPS guidance lifted to $8.40‑$8.55 for 2026.

Pulse Analysis

Zimmer Biomet’s first‑quarter results demonstrate a rare blend of top‑line expansion and margin resilience in a competitive orthopedic landscape. Revenue climbed to $2.087 billion, propelled by a 9.3% reported increase and solid organic growth, while adjusted gross margin expanded to 73% thanks to favorable product mix and a one‑time tariff refund. Operating cash flow of $359 million and free cash flow of $246 million provided ample liquidity for a $250 million share‑repurchase program, reinforcing confidence among shareholders.

Innovation remains the engine of Zimmer Biomet’s growth trajectory. The Technology & Data segment surged nearly 12%, driven by robust sales of the ROSA robotic platform and the TMINI handheld system. In the United States, the Oxford Partial Cementless Knee delivered more than 20% sales acceleration, highlighting the market’s appetite for cementless solutions. The recent Paragon 28 acquisition is already delivering incremental revenue, with a 200‑basis‑point acceleration in Q1, and is expected to contribute further to reported sales growth. Concurrently, the company’s sales‑force transformation—reducing 1099 contractors and expanding specialized reps—has begun to lift productivity in newly dedicated territories.

Looking ahead, Zimmer Biomet reaffirmed its 2026 organic revenue guidance of 1%‑3% constant‑currency growth while raising adjusted EPS expectations to $8.40‑$8.55 and free‑cash‑flow growth to 9%‑11%. Margins are projected to dip modestly, reflecting acquisition dilution and continued investment in commercial infrastructure. The leadership transition, with Paul Stellato stepping in as interim CFO, adds stability as the firm pursues operational excellence, strategic acquisitions, and the rollout of next‑generation robotic and smart‑implant technologies. These initiatives position Zimmer Biomet to capture market share and deliver sustained shareholder value.